Amgen Inc. (AMGN)

240.69
NASDAQ
Prev Close 241.55
Day Low/High 238.57 / 243.62
52 Wk Low/High 177.05 / 264.97
Exchange NASDAQ
Shares Outstanding 585.69B
Market Cap 141.47B
P/E Ratio 19.71
Div & Yield N.A. (N.A)

Latest News

Regeneron, PayPal, Facebook Push Up Real Money Post Industrial Average

Regeneron, PayPal, Facebook Push Up Real Money Post Industrial Average

The RMPIA rose 3.2% for May and 3.3% for the first five months of 2020.

Buffett's Great Airline Escape, Tech Leadership, ECB Wiggle Room

Buffett's Great Airline Escape, Tech Leadership, ECB Wiggle Room

Don't just follow the herd, time your exits and entrances well -- even if it is a big player like Warren Buffett that is leading the charge.

Trading Volumes Rising, GDP Forecasts, Earnings and Trading Thoughts

Trading Volumes Rising, GDP Forecasts, Earnings and Trading Thoughts

Market leadership may be lacking on Thursday despite rising trading volumes, plus an update on Apple, Microsoft, Mastercard, Amazon and Gilead.

Amgen Looks Set to Soar to New Heights - Despite the Naysayers

Amgen Looks Set to Soar to New Heights - Despite the Naysayers

Here's how to play the biotech with earnings on the horizon.

The Market Refuses to Embrace Negatives as Major Earnings Reports Roll In

The Market Refuses to Embrace Negatives as Major Earnings Reports Roll In

So far, earnings season has not been the obstacle that many have feared.

Jim Cramer: Here Are the Stocks That 'Transom' Money Is Buying

Jim Cramer: Here Are the Stocks That 'Transom' Money Is Buying

They buy and buy and buy. The same stocks. Over and over. No end to it.

Real Money Post Industrial Average Leads, but Coronavirus Adds Uncertainty

Real Money Post Industrial Average Leads, but Coronavirus Adds Uncertainty

RMPIA ended January up 0.8%, but now the damage from the Wuhan virus is weighing on the future.

Amgen Cut to Underperform at Baird

The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon

The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon

It's no secret that the Fed would like to get out of the short-term repo business.

Market Prices in New Risk, Action for 9 Stocks in My Portfolio: Market Recon

Market Prices in New Risk, Action for 9 Stocks in My Portfolio: Market Recon

What I suggest individual investors do is give their portfolios a physical. Like a visit to the doctor.

My Pick for 2020? You Won't Believe It's Been on Your Screen All Along

My Pick for 2020? You Won't Believe It's Been on Your Screen All Along

This company made headlines in 2019, and I'm betting on it as a great play -- in many senses of the word -- for this new year.

3 Boomer-Inspired Drug Plays With Dividend Appeal

3 Boomer-Inspired Drug Plays With Dividend Appeal

Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.

Amgen Gets Shot in the Arm, Could Bounce Up in Months Ahead

Amgen Gets Shot in the Arm, Could Bounce Up in Months Ahead

AMGN appears to have taken a turn for the better and is now looking at targets of $254 and $270.

RMPIA Lags in November, but Trounces S&P 500 for Quarter, Year So Far

RMPIA Lags in November, but Trounces S&P 500 for Quarter, Year So Far

Now, many Real Money Post Industrial Average stocks should see a boost from the holiday splurge by shoppers.

News While You Slept, Semi Tough and Updates on Amgen and Splunk: Market Recon

News While You Slept, Semi Tough and Updates on Amgen and Splunk: Market Recon

Also, Fed Chairman Powell says there are no plans for a U.S. digital currency (for now), plus Tesla's electric pickup.

Real Money Post Industrial Average Exits October on Top

Real Money Post Industrial Average Exits October on Top

The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.

Drug Companies Are a Political Football, Trading Amgen: Market Recon

Drug Companies Are a Political Football, Trading Amgen: Market Recon

The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.

We Prescribe Amgen to Treat Your Portfolio

We Prescribe Amgen to Treat Your Portfolio

According to the charts, the drugmaker should break out to new highs.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Sussing the Fed -- Plus Apple, Amgen and Other Earnings: Market Recon

Sussing the Fed -- Plus Apple, Amgen and Other Earnings: Market Recon

Markets are watching what Fed Chair Powell will signal for future rate cuts during this afternoon's FOMC rate decision.

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.

Jim Cramer: Demand Is Driving This Market to All-Time Highs

Jim Cramer: Demand Is Driving This Market to All-Time Highs

The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.

Arrowhead Pharmaceuticals Is Flying Higher on the Charts

Arrowhead Pharmaceuticals Is Flying Higher on the Charts

Before I give my recommendation I want to visit with the charts and indicators.

Real Money Post-Industrial Average Continues to Outpace Major Indices

Real Money Post-Industrial Average Continues to Outpace Major Indices

RMPIA is up 20.9% in the first nine months of 2019.

Jim Cramer: How to Survive This Violent Rotation

Jim Cramer: How to Survive This Violent Rotation

Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.

Could Small Drug Trial Hold Big Potential for Amgen?

Could Small Drug Trial Hold Big Potential for Amgen?

The results of a lung-cancer drug got me to go long on the stock, but the larger picture is complicated.

Amgen's Lower Open Tests Support but the Bigger Picture Is More Important

Amgen's Lower Open Tests Support but the Bigger Picture Is More Important

Let's check out the charts to get a sense of where prices could be headed.